Trevi Therapeutics, Inc.
TRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,328 | $713 | $740 | $437 |
| - Cash | $57 | $117 | $19 | $34 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1,272 | $597 | $721 | $404 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |
| Net Income | -$12 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.08 | -0.094 | -0.088 | -0.11 |
| % Growth | 15.3% | -7.4% | 20.1% | – |
| Operating Cash Flow | -$11 | -$10 | -$13 | -$10 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$11 | -$10 | -$13 | -$10 |